Regenxbio gene therapy refiling plan derailed by FDA hold over spine MRI findings
2 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Regenxbio gene therapy refiling plan derailed by FDA hold over spine MRI findings" is generating significant coverage in the Business category, with 2 articles from 2 distinct sources tracked by PULSE so far.
Outlets currently covering the story include BioSpace and BioPharma Dive. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 8h ago.
Quick answers
Why is "Regenxbio gene therapy refiling plan derailed by FDA hold over spine MRI finding" trending?
Because 2 independent news sources published 2 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (2)
- REGENXBIO’s Hunter syndrome gene therapy hit by FDA hold, stymieing resubmission plans BioSpace · 2d ago
- Safety concerns spur FDA to again halt testing of Regenxbio gene therapy BioPharma Dive · 2d ago
Topics
Related trends
FDA Approves Drug for Pancreatic Cancer in Milestone for Treatment of Deadly Disease
3 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
FDA Authorizes First Wearable Device to Continuously Monitor Glucose, Ketones
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Thyroid tablets recalled nationwide over potential ‘superpotency’: FDA
A nationwide recall has been issued for thyroid medication following reports of potential 'superpotency' issues affecting the tablets.
HHS plans new FDA deputy commissioner roles for technology and drugs, sources say
The U.S. Department of Health and Human Services plans to expand the FDA's leadership structure with new deputy commissioner roles for technology and drugs.
FDA pauses Regenxbio gene therapy trial again due to safety concerns
The FDA has placed a clinical hold on Regenxbio's gene therapy for Hunter Syndrome following safety concerns related to spine MRI findings.
FDA Approves Alzheimer’s Blood Test Developed by Roche and Eli Lilly
The FDA has granted clearance to a first-of-its-kind blood test for Alzheimer's biomarkers developed through a partnership between Roche and Eli Lilly.